Skip to main content

Table 17 hsCRP, mg/L

From: A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjects with hyperuricemia

Groups

Baseline

4 weeks

Mean % Change

12 weeks

Mean % Change

24 weeks

Mean % Change

A

7.37 ± 0.97

7.08 ± 0.95

− 3.96 ± 1.49

6.63 ± 0.97

− 10.14 ± 2.31

5.94 ± 0.95

−19.66 ± 3.46

B

7.80 ± 0.97

7.73 ± 0.97

− 0.86 ± 1.18

7.41 ± 0.92

− 5.05 ± 1.98

7.03 ± 0.92

− 9.86 ± 2.68

C

8.41 ± 1.11

8.11 ± 1.10

− 3.66 ± 1.32

7.72 ± 1.07

−8.30 ± 2.33

7.26 ± 1.04

− 13.76 ± 2.53

Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us